RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 13
OP 14
DO 10.1177/155989771448007
UL http://mdc.sagepub.com/content/14/48/13.abstract
AB Sofosbuvir (SOF)has potent activity against hepatitis C virus (HCV). Unpublished studies have also indicated the anti-HCV activity of GS-5816, and the high SVR following a 12-week regimen in noncirrhotic, treatment-naïve HCV patients. These studies spurred the phase 2, open-label, ELECTRON-2 study evaluating the efficacy and safety of an 8-week regimen of SOF + GS-5816 in noncirrhotic, treatment-naïve patients infected with HCV genotype 3, as discussed in this article.